Abstract
Background: Proliferation of the smooth muscle and epithelial cells within the prostatic transition zone in older men leads to benign prostatic hyperplasia (BPH), which is hallmarked by the troublesome lower urinary tract symptoms. The affair responsible for the initiation and promotion of disease is still unresolved, though alpha-blockers and 5α-reductase inhibitors are used as management options for relief from the dynamic and static components respectively.
Method: Combination therapy including both the alpha blocker and 5α-reductase inhibitor is emerging as inclusive parcel for treatment. However, selective androgen receptor modulators (SARM) and selective estrogen receptor modulators (SERM) are the other management resources, which are in the limelight. Result: This review gives a glimpse of BPH and the various chemical entities which have been reported in literature till date for the condition since 2005.Keywords: 5α-reductase inhibitors, alpha-blockers, benign prostatic hyperplasia, SARM, SERM.
Mini-Reviews in Medicinal Chemistry
Title:Evolving Novel Chemical Entities for Management of Benign Prostatic Hyperplasia#
Volume: 17 Issue: 7
Author(s): Sonal Gupta, Gopal Gupta and V. L. Sharma*
Affiliation:
- Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extn., Lucknow-226031, Uttar Pradesh,India
Keywords: 5α-reductase inhibitors, alpha-blockers, benign prostatic hyperplasia, SARM, SERM.
Abstract: Background: Proliferation of the smooth muscle and epithelial cells within the prostatic transition zone in older men leads to benign prostatic hyperplasia (BPH), which is hallmarked by the troublesome lower urinary tract symptoms. The affair responsible for the initiation and promotion of disease is still unresolved, though alpha-blockers and 5α-reductase inhibitors are used as management options for relief from the dynamic and static components respectively.
Method: Combination therapy including both the alpha blocker and 5α-reductase inhibitor is emerging as inclusive parcel for treatment. However, selective androgen receptor modulators (SARM) and selective estrogen receptor modulators (SERM) are the other management resources, which are in the limelight. Result: This review gives a glimpse of BPH and the various chemical entities which have been reported in literature till date for the condition since 2005.Export Options
About this article
Cite this article as:
Gupta Sonal, Gupta Gopal and Sharma L. V.*, Evolving Novel Chemical Entities for Management of Benign Prostatic Hyperplasia#, Mini-Reviews in Medicinal Chemistry 2017; 17 (7) . https://dx.doi.org/10.2174/1389557516666160630115819
DOI https://dx.doi.org/10.2174/1389557516666160630115819 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Applications of Nanomaterials Based on Electrochemical Drug Analysis
Current Analytical Chemistry Pulmonary Arterial Hypertension: Need to Treat
Inflammation & Allergy - Drug Targets (Discontinued) Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms
Current Neuropharmacology Molecular and Cellular Mechanisms in the Pathophysiology of Severe Head Injury
Current Pharmaceutical Design Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design Functions of Third Extracellular Loop and Helix 8 of Family B GPCRs Complexed with RAMPs and Characteristics of their Receptor Trafficking
Current Protein & Peptide Science Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Targeting Trypanosoma cruzi Platelet-activating Factor Receptors: Scope for the Development of Novel Drugs to Treat Chagas Disease
Mini-Reviews in Medicinal Chemistry Current Key Points in Management for Severe Community-Acquired Pneumonia
Current Respiratory Medicine Reviews Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease
Current Pharmaceutical Design The ONTARGET Trial Programme: Facts and Lessons
Current Hypertension Reviews Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets
Cardiovascular & Hematological Disorders-Drug Targets Cysteine-Rich Mini-Proteins in Human Biology
Current Topics in Medicinal Chemistry Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Current Role and Future Perspectives of Radioiodinated MIBG in the Evaluation of Dementia with Lewy Bodies
Current Radiopharmaceuticals Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry Non-Analgesic Effects of Opioids: Opioids’ Effects on Sleep (Including Sleep Apnea)
Current Pharmaceutical Design